What is Sharps Technology?
Based in Melville, New York, Sharps Technology operates at the intersection of medical engineering and public health. The company specializes in the development of smart safety syringes, a critical innovation designed to eliminate the two million potentially infectious accidental needlestick injuries occurring annually. By integrating advanced safety mechanisms into standard delivery systems, Sharps Technology is effectively reducing occupational hazards for healthcare professionals while simultaneously lowering the long-term liability costs associated with needle-related infections for hospital systems and clinical facilities.
The company's market position is defined by its commitment to high-volume manufacturing and regulatory compliance, ensuring that its safety-first solutions are accessible to a broad spectrum of medical providers. As the healthcare industry continues to emphasize patient and provider safety, Sharps Technology remains at the forefront of this essential technological evolution.
How much funding has Sharps Technology raised?
Sharps Technology has raised a total of $814.4M across 3 funding rounds:
Share Placement
$3.5M
Stock/Share Issuance
$400M
Private Equity
$410.9M
Share Placement (2024): $3.5M with participation from Aegis Capital Corp
Stock/Share Issuance (2025): $400M, investors not publicly disclosed
Private Equity (2025): $410.9M, investors not publicly disclosed
Key Investors in Sharps Technology
Aegis Capital Corp
Aegis Capital Corporation is a full-service investment banking firm with over 35 years of experience, providing institutional clients with equity research, private equity, and strategic financial advisory services.
Undisclosed Institutional Investor
An undisclosed investor participating in the funding round, focusing on high-growth medical technology and healthcare infrastructure.
Undisclosed Private Equity Firm
An undisclosed investor participating in the funding round, specializing in late-stage private equity and enterprise-level medical device scaling.
What's next for Sharps Technology?
With the recent injection of capital, Sharps Technology is poised to transition into a phase of aggressive market penetration and operational expansion. The strategic focus will likely shift toward scaling production capacity to meet the rising demand for safety-engineered medical devices. Furthermore, the company is expected to leverage this financial backing to strengthen its intellectual property portfolio and potentially explore new distribution partnerships within the global healthcare supply chain.
The current funding context suggests that Sharps Technology is moving beyond the development phase and into a period of sustained commercialization. Investors are closely monitoring the company's ability to integrate its technology into large-scale clinical environments, which will be the primary driver of long-term value creation and market dominance in the safety syringe segment.
